Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Aims: Resting heart rate (RHR) has been shown to be associated with cardiovascular outcomes in various conditions. It is unknown whether different levels of RHR and different associations with cardiovascular outcomes occur in patients with or without diabetes, because the impact of autonomic neuropathy on vascular vulnerability might be stronger in diabetes. Methods and results: We examined 30 937 patients aged 55 years or older with a history of or at high risk for cardiovascular disease and after myocardial infarction, stroke, or with proven peripheral vascular disease from the ONTARGET and TRANSCEND trials investigating ramipril, telmisartan, and their combination followed for a median of 56 months. We analysed the association of mean achieved RHR on-treatment with the primary composite outcome of cardiovascular death, myocardial infarction, stroke, hospitalization for heart failure, the components of the composite primary outcome, and all-cause death as continuous and categorical variables. Data were analysed by Cox regression analysis, ANOVA, and χ2 test. These trials were registered with ClinicalTrials.gov.number NCT00153101. Patients were recruited from 733 centres in 40 countries between 1 December 2001 and 31 July 2008 (ONTARGET) and 1 November 2001 until 30 May 2004 (TRANSCEND). In total, 19 450 patients without diabetes and 11 487 patients with diabetes were stratified by mean RHR. Patients with diabetes compared to no diabetes had higher RHRs (71.8 ± 9.0 vs. 67.9 ± 8.8, P < 0.0001). In the categories of <60 bpm, 60 ≤ 65 bpm, 65 ≤ 70 bpm, 70 ≤ 75 bpm, 75 ≤ 80 bpm and ≥80 bpm, non-diabetic patients had an increased hazard of the primary outcome with mean RHR of 75 ≤ 80 bpm (adjusted hazard ratio [HR] 1.17 (1.01–1.36)) compared to RHR 60 ≤ 65 bpm. For patients with in-trial RHR ≥80 bpm the hazard ratios were highest (diabetes: 1.96 (1.64–2.34), no diabetes: 1.73 (1.49–2.00), For cardiovascular death hazards were also clearly increased at RHR ≥80 bpm (diabetes [1.99, (1.53–2.58)], no diabetes [1.73 (1.38–2.16)]. Similar results were obtained for hospitalization for heart failure and all-cause death while the effect of RHR on myocardial infarction and stroke was less pronounced. Results were robust after adjusting for various risk indicators including beta-blocker use and atrial fibrillation. No significant association to harm was observed at lower RHR. Conclusion: Mean RHR above 75–80 b.p.m. was associated with increased risk for cardiovascular outcomes except for stroke. Since in diabetes, high RHR is associated with higher absolute event numbers and patients have higher RHRs, this association might be of particular clinical importance in diabetes. These data suggest that RHR lowering in patients with RHRs above 75–80 b.p.m. needs to be studied in prospective trials to determine if it will reduce outcomes in diabetic and non-diabetic patients at high cardiovascular risk. Clinical Trial registration: http://clinicaltrials.gov.Unique identifier: NCT00153101.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RHR is associated with heart disease [31], diabetes [32], cancer [33], and all-cause, cardiovascular- and cancer-specific mortality [34,35] but the mechanisms underlying these are not fully understood.”
From Resting heart rate is a population-level biomarker of cardiorespiratory fitness: The Fenland Study (2023) · cites this paper as [31]
Citations
Cites
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Flexible regression models with cubic splines
Durrleman, S., & Simon, R. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080504 · Cited by 2,689
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citationMozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Després, J.-P., Fullerton, H. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000366 · Cited by 2,466
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Self-citationAuthors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,334
Self-citationBöhm, M., Swedberg, K., Komajda, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61259-7 · Cited by 1,099
Self-citationHyperpolarization-Activated Cation Channels: From Genes to Function
Biel, M., Wahl-Schott, C., Michalakis, S., & Zong, X. (2009) · Physiological Reviews · doi:10.1152/physrev.00029.2008 · Cited by 1,003
Cited by
Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management
Williams, S., Raheim, S. A., Khan, M. I., Rubab, U., Kanagala, P., Zhao, S. S., Worthington, A., Brown, E. E., & Alam, U. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.09.002 · Cited by 112
Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension
Böhm, M., Tsioufis, K. P., Kandzari, D. E., Kario, K., Weber, M. A., Schmieder, R. E., Townsend, R. R., Kulenthiran, S., Ukena, C., Pocock, S., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.044 · Cited by 54
Self-citationPapaioannou, T. G., Oikonomou, E. K., Lazaros, G. A., Christoforatou, E., Vogiatzi, G., Tsalamandris, S., Chasikidis, C., Kalambogias, A., Mystakidi, V.-X., Galiatsatos, N., et al. (2019) · Physiological Measurement · doi:10.1088/1361-6579/ab165f · Cited by 51
“…and clinical studies have shown that elevated resting heart rate is significantly associated with adverse cardiovascular (CV) events, CV death and all-cause mortality in various populations (Aune et al 2017, 1361-6579 5 1 9 4 June 2019 Sharashova et al 2017, Bohm et al 2018, O’Brien et al 2018).”
BackgroundImahori, Y., Vetrano, D. L., Xia, X., Grande, G., Ljungman, P. L. S., Fratiglioni, L., & Qiu, C. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12495 · Cited by 51
Resting heart rate is a population-level biomarker of cardiorespiratory fitness: The Fenland Study
Gonzales, T. I., Jeon, J. Y., Lindsay, T., Westgate, K., Perez-Pozuelo, I., Hollidge, S., Wijndaele, K., Rennie, K., Forouhi, N., Griffin, S., et al. (2023) · PLOS ONE · doi:10.1371/journal.pone.0285272 · Cited by 44
“RHR is associated with heart disease [31], diabetes [32], cancer [33], and all-cause, cardiovascular- and cancer-specific mortality [34,35] but the mechanisms underlying these are not fully understood.”
Background
Metadata
- Authors
- Böhm, M., Schumacher, H., Teo, K. K., Lonn, E. M., Mahfoud, F., Ukena, C., Mann, J. F. E., Mancia, G., Redon, J., Schmieder, R. E., Sliwa, K., Marx, N., Weber, M. A., Williams, B., & Yusuf, S.
- Affiliations
- Universitätsklinikum des Saarlandes (DE)
- Statistical Consultant , 55218 Ingelheim, Germany
- Population Health Research Institute (CA)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Milano-Bicocca (IT)
- Hypertension Unit, Hospital CIínico Universitario, University of Valencia , Av. de Blasco Ibáñez, 13, 46010 València, Spain
- University of Cape Town (ZA)
- Universitätsklinikum Aachen (DE)
- State University of New York (US)
- National Institute for Health and Care Research (GB)
- Corresponding author
- Böhm, Michael
- ORCID
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-12-24
- Volume
- 41
- Issue
- 2
- Pages
- 231-238
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2906096545
- Cited by
- 55
- References
- 41
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 6 · 2023: 11 · 2022: 8 · 2021: 9 · 2020: 6 · 2019: 1
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Steering Committees of ONTARGET and TRANSCEND
- Deutsche Forschungsgemeinschaft (SFB TTR 219)
- Astra Zeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- resting heart rate, cardiovascular outcomes, diabetes mellitus, autonomic neuropathy, cardiovascular risk, ramipril, telmisartan, ONTARGET trial, TRANSCEND trial, cardiovascular mortality, myocardial infarction, stroke, heart failure hospitalization, all-cause mortality, ACE inhibitors, angiotensin receptor blockers, high cardiovascular risk patients, elderly patients
- MeSH terms
- Heart Disease Risk Factors, Cardiovascular Diseases, Diabetes Mellitus, Female, Heart Rate, Humans, Male, Middle Aged, Prospective Studies, Rest, Risk Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. https://app.cochat.ai/papers/10.1093/eurheartj/ehy808
- The paper
- Böhm, M., Schumacher, H., Teo, K. K., Lonn, E. M., Mahfoud, F., Ukena, C., Mann, J. F. E., Mancia, G., Redon, J., Schmieder, R. E., Sliwa, K., Marx, N., Weber, M. A., Williams, B., & Yusuf, S. (2020). Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. European Heart Journal. https://doi.org/10.1093/eurheartj/ehy808
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.